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Abstract
Background: Most patients who experience virologic failure (VF) on second line antiretroviral therapy (ART) in
low-middle income countries fail due to poor adherence rather than antiretroviral resistance. A simple adherence
tool designed to detect VF would conserve resources by rationally limiting need for viral load (VL) testing and, in
those countries with access to third line ART, the need for resistance testing.
Methods: We conducted an observational cohort study of patients who initiated second line ART at a clinic in
Kwazulu-Natal, South Africa. Using clinical and pharmacy refill data extracted from the clinic’s electronic database,
we determined risk factors for VF. Three different methods of calculating short term pharmacy refill adherence were
evaluated and compared with long term adherence since second line initiation. We also explored the ability of
differing durations of short term pharmacy refill to predict VF on second line ART.
Results: We included 274 patients with a median follow up of 27 months on second line ART. VF ranged between
3% and 16% within each six month interval after initiating second line ART. 243 patients with at least one VL after
4 months on second line were analysed in the statistical analysis. Pharmacy refill adherence assessed over shorter
periods (4 to 6 months) predicted virologic suppression as well as pharmacy refill assessed over longer periods. The
risk of VF fell 73% with each 10% increase in adherence measured from pharmacy refills over a 4 month period.
Low CD4 count at second line ART initiation was a significant independent risk factor for VF.
Conclusion: Patients identified as poorly adherent by short term pharmacy refill are at risk for VF on second line
ART. This pragmatic adherence tool could assist in identifying patients who require adherence interventions, and
help rationalize use of VL monitoring and resistance testing among patients on second line ART.
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Background
Approximately 500 000 people in low-middle income
countries were estimated to be on second line protease in-
hibitor (PI)-based ART in 2012, and this number is ex-
pected to increase exponentially [1]. A systematic review
reported virologic failure (VF) rates on second line ART
in resource-limited settings to be as high as 38% after
3 years [2]. Risk factors for VF on second line ART include
a lower CD4 count and the presence of WHO clinical
stage 4 conditions at second line switch, [3-6], a longer
duration between confirmed VF on first line and initiating
second line, [7] changing one nucleoside/nucleotide re-
verse transcriptase inhibitor (NRTI) instead of two at sec-
ond line ART initiation, [8] and poor adherence on
second line ART [9]. The majority of patients with VF on
second line ART have no major PI mutations, indicating
that VF in most cases is not the result of antiretroviral re-
sistance [10-12]. Identifying which patients on second line
ART are at risk of developing VF will allow earlier imple-
mentation of adherence interventions and may rationalize
the use of VL monitoring, which is not widely available in
many low-income countries. The development of policies
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for a third line ART regimen is regarded as a priority by
the World Health Organization (WHO) [13]. Empirically
switching patients failing second line ART to third line
ART, which is currently expensive, would be a waste of re-
sources as most patients do not have antiretroviral resist-
ance. Switching to third line ART should ideally be guided
by genotype antiretroviral resistance testing (GART), but
this is currently expensive and has little availability in re-
source limited settings. A simple predictor of VF on sec-
ond line ART could also be useful in selecting patients
who may benefit from GART.
Pharmacy refill is an adherence measure, which has
been shown to correlate well with survival and virologic
suppression [14-16]. A recent study from our group (of
an earlier cohort from the same clinic from which the
cohort used in the current study was obtained) showed
that adherence measured by pharmacy refill correlated
with virologic suppression on second line ART, but this
was based on average adherence since starting second
line [9]. A more pragmatic measure would be to assess
adherence over the short term, which has been shown to
predict VF in a small study in a high income country
setting [17].
We investigated the association between short term
adherence, assessed by pharmacy refill, and VF in pa-
tients on second line ART at a clinic in Kwazulu-Natal,
South Africa, in order to develop a clinical tool for use
in ART programmes in low-middle income settings.
Methods
Study population and setting
The McCord Hospital ART clinic, “Sinikithemba” meaning
in Zulu “we give hope”, provided HIV care for patients
from Durban and surrounding areas in Kwazulu-Natal,
South Africa with financial support from the President’s
Emergency Plan for AIDS Relief and the South African
Department of Health. Approximately 8200 adults and
1200 children received ART at the clinic until its closure
in February 2012. The clinic followed national recommen-
dations, which at the time included VL and CD4 count
monitoring six-monthly after ART initiation. During the
period of study, the standard South African second line
regimen consisted of lopinavir/ritonavir with two NRTIs.
As per WHO guidelines, second line initiation occurred
either for toxicity/intolerability of first line drugs or for
confirmed VF on first line ART [13]. Patients identified
with VF on second line ART (>1000 copies/ml) after a
minimum of six months of therapy, were referred for ad-
herence counselling with a repeat VL measurement after
three months.
Inclusion and exclusion criteria
We identified HIV-infected adults over 18 years of age
who initiated second line ART following VF on first line
ART between August 2003 and June 2011. Patients who
switched to second line ART for reasons other than VF
on first line were excluded. In an exploratory analysis we
discovered several patients with suppressed VL despite
zero adherence, indicating that they were obtaining ART
from another site. For the statistical analysis, we there-
fore excluded patients with suppressed VL following a
four month period of null adherence.
Clinical and demographic data was extracted from the
clinic’s electronic database. including age, sex, CD4 and
VL responses, and duration on second line ART. The
date of each pharmacy refill as well as the number of
pills dispensed was also recorded. A 30 day supply of
medication was routinely dispensed with pharmacy re-
fills scheduled after 28 days. Stable patients with viro-
logic suppression were occasionally given 60 or 90 days
of medication with an appropriate follow up interval.
Missed pharmacy refill dates resulted in a reminder tele-
phone call from the clinic.
Study design
We conducted a retrospective observational cohort
study of patients who initiated second line ART after
confirmed VF on first line. We analysed the relationship
between short term adherence measured by pharmacy
refill and virologic suppression. We identified factors as-
sociated with VF and evaluated three different short
term measures of pharmacy refill adherence and com-
pared them with long term adherence measured from
second line ART initiation. In addition, we explored the
optimum duration of short term refill which correlated
best with a virologic response.
Statistical analysis
We performed all statistical analyses in Stata version 13.
The pharmacy refill period before each VL (after a mini-
mum of 4 months on second line ART) was used to ana-
lyse the relationship between pharmacy refill adherence
and virologic suppression. We ensured that our method
accommodated patients who had collected more than
30 days of medication at a single visit within the period
being assessed. The association between pharmacy refill
adherence and virologic suppression was evaluated using
Receiver Operator Characteristics (ROC). We compared
several methods of calculating adherence from pharmacy
refill data over differing periods. We assessed both short
term (from 3 to 12 months) and long term pharmacy re-
fill (from second line initiation). We truncated adher-
ence over 100% for all methods.
Short term adherence was expressed as a percentage
and calculated using three different methods, termed
“interval gap”, “interval average” and “interval crude”.
“Interval crude”, was calculated by dividing the number
of pharmacy refills within the interval (numerator); by
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the number of months within the interval (denomin-
ator). “Interval average”, which is similar to a method
published in a previous study on short term pharmacy
refill adherence, [15] was calculated as follows: number
of days of medication dispensed within the interval, plus
the accrued days of medication from the last dispensing
event prior to the interval, less the unused days of medi-
cation from the last dispensing event within the interval
(numerator); divided by the number of days with the
interval (denominator). “Interval gap” is a short term
pharmacy refill adherence measure which accounts more
accurately for gaps in medication days. The “interval
average” method may over-estimate adherence, because
patients receive 30 days’ supply at scheduled dispensing
events every 28 days, therefore, if patients have a gap
without medication but then attend subsequent sched-
uled dispensing events, the accrued two day supply for
each dispensing event within the interval will be in-
cluded in the numerator, reducing the days of medica-
tion missed. For each day within the interval, we
determined whether the patients had medication accord-
ing to the pharmacy refill data, allowing accrued tablets
from the last dispensing event prior to the interval as
with the “interval average” method. “Interval gap” was
calculated as follows: the number of days within the
period, less the number of days that the patient did not
have medication (numerator); divided by the number of
days within the period (denominator). Long term “over-
all” adherence was determined by dividing the total
number of days of medication dispensed since second
line initiation (numerator), by the total number of days
since second line initiation prior to the VL of interest
(denominator).
Associations between virologic suppression and the
different adherence measures were determined using the
area under the curve derived from receiver operating
characteristic (ROC) analyses, assessed over differing
interval durations prior to a VL of 3 to 12 months. The
best performing short term adherence measure and
interval duration prior to a VL was then selected for
subsequent analyses. We determined the association be-
tween virologic suppression and the identified variables
in a multivariate logistic regression model. The variables
included age, sex, CD4 and log10 VL at second line initi-
ation, duration on second line, and adherence measured
by short term pharmacy refill prior to a VL. Missing
CD4 and VL values at second line initiation were im-
puted. The square root of the CD4 was used to attenuate
the effect of higher values.
Ethics
This study was reviewed and approved by the University
of Cape Town Human Research Ethics Committee and
the McCord Research Ethics Committee.
Results
Two hundred and ninety one patients met the inclusion
criteria for the study, but there was missing data in 17
patients, who were excluded. The baseline characteristics
of the 274 included patients are shown in Table 1. The
proportions of patients with virologic suppression and
VF over time on second line are shown in Table 2. For
the subsequent analyses, we excluded 21 patients who
had no VL data ≥4 months after starting second line and
a further 10 patients who had suppressed VL following a
4 month period of zero adherence, leaving 243 patients.
Adherence measured by the “interval gap” method
out-performed both the “interval average” and “interval
crude” methods. (Figure 1) Adherence measured by the
“interval gap” method performed similarly over all of the
interval durations assessed, with overlapping 95% confi-
dence intervals of the ROC area under the curve. We
chose 4 months of adherence measured by the “interval
gap” method for subsequent analyses as a pragmatic
time period to implement in clinics, considering that
Table 1 Patient characteristics at initiation of second line
ART (numbers in brackets = interquartile range)
No of females 54.4% (149/125)
Median age in years 35 (32 – 42)
Median CD4 at baseline (n = 251) 174 (107 – 265)
Median log10 VL at baseline (n = 261) 4.1 (3.6 – 4.7)
Median no of months followed up 27 (15 – 47)
Table 2 VL suppression over time
Months after starting second line
6 12 18 24 30 36 42 48
No of patients in care 252 228 180 146 112 87 72 54
No with VL results 223 197 160 124 97 78 69 45
No with VL <50 159 (71%) 155 (79%) 115 (72%) 97 (78%) 77 (79%) 58 (74%) 48 (70%) 33 (73%)
No with VL <400 195 (87%) 169 (86%) 132 (83%) 107 (86%) 88 (91%) 69 (88%) 60 (87%) 40 (89%)
No with VL ≥1000 22 (10%) 26 (13%) 26 (16%) 16 (13%) 7 (7%) 7 (9%) 2 (3%) 4 (8%)
Note that the 6 monthly VL data reflect a window (e.g. a VL between 9 and 15 months was categorised as a 12 month VL).
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achievement of virologic suppression on a new regimen
is usually attained by 4 months. Short term pharmacy
refill measured 4 months prior to a VL predicted viro-
logic response, with higher rates of adherence achieving
superior virologic suppression (Figure 2). The ROC
curve for the “interval gap” method over 4 months dur-
ation is shown in Figure 3. Adherence measured by the
“interval gap” method was equivalent to long term “over-
all” adherence at predicting virologic suppression (<400
copies/ml) – data not shown.
Significant risk factors for VF on multivariate analysis
were poor adherence measured by 4 months of “interval
gap” pharmacy refill proximal to a VL and a lower CD4
count at second line initiation (Table 3).
Discussion
We have demonstrated that short term adherence mea-
sured by pharmacy refill was the strongest predictor of VF
on second line ART. Short term pharmacy refill adherence
was also associated with virologic suppression with an “ad-
herence dose response” relationship. Our study is one of
few which have evaluated adherence on second line ART
and is novel in that adherence was measured over the
short term. We found that the “interval gap” method,
which is a method not previously used for calculating ad-
herence from ART pharmacy refills, outperformed the
usual methods that average adherence over an interval.
We observed a trend towards an association between lon-
ger duration of second line ART and risk for VF, but this
was not statistically significant. We found an association
between lower CD4 count at the time of starting second
line ART and VF on second line ART, which adds support
to data showing that second line outcomes are improved
with early detection of failure of first line ART and prompt
initiation of second line ART before immunological de-
terioration [18].
A previous report of an earlier cohort from the same
clinic as the present study, [9] reported an association be-
tween virologic suppression on second line ART and adher-
ence measured by pharmacy refill over the long term since
second line ART initiation. Pharmacy refill as an adherence
measure over shorter time periods is more pragmatic and
implementable [19]. In our study short term “interval gap”
refill performed similarly to long term “overall” refill on
ROC analysis, and out-performed other methods of deter-
mining short term adherence using pharmacy refills. We
explored the ability of differing durations of pharmacy re-
fill from three to twelve months to predict VF: “interval
Figure 1 Area under the receiver operator characteristics curve
comparing “interval gap”, “interval average” and “interval
crude” short term pharmacy refill methods over varying
durations prior to the viral load of interest. Error bars denote
95% confidence intervals.
Figure 2 Pharmacy refill adherence, measured by the “interval gap” method over 4 months, and virologic suppression. Error bars denote
upper 95% confidence intervals.
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crude” and “interval average” performed better with longer
durations, but the best performing method, “interval gap”,
performed similarly over all of the interval durations
assessed. Grossberg et al. demonstrated that a 90 day
period of pharmacy refill was associated with VL change,
[19] but refill periods shorter than 60 days may overcall
imperfect adherence leading to unnecessary clinical inter-
ventions [17]. We found that 80% adherence by pharmacy
refill over 4 months appeared to be a threshold for pre-
dicting virologic suppression (Figure 2). However, there
were small numbers of patients in the lower adherence
strata, which limited our ability to determine a threshold.
Others have reported an increased risk of VF with adher-
ence <80% in observational studies of patients on boosted
PI regimens [8,20]. A threshold of 80% adherence mea-
sured by pharmacy refill in the previous 4 months could
be used to identify patients needing enhanced adherence
support and rationalise use of VL testing in resource-
limited settings. Most patients on second line ART ex-
periencing VF were able to achieve virologic suppres-
sion with intensified adherence support in a study at a
clinic in South Africa [21]. VF on second line ART is
likely a result of poor adherence rather than resistance
as several studies have found a low proportion of major
PI mutations in patients with VF on second line ART
[10-12]. Unfortunately, as a result of high cost, the rou-
tine use of GART in patients with VF on second line
will not be widely available in most low-middle income
countries. Van Zyl et al. [12] suggested an algorithm to
select patients in VF on second line for GART using
lopinavir plasma and hair therapeutic drug monitoring.
However, these pharmacokinetic measures are costly
(although less costly than GART) and have extremely
limited availability in resource-limited settings. By con-
trast, short term adherence measured by pharmacy re-
fill can be easily implemented, especially in clinics with
Figure 3 Receiver operator characteristics curve illustrating the “interval gap” method over 4 months.
Table 3 Factors associated with VF among patients on second line ART
Variables Univariate Multivariate
Odds ratio p-value Adjusted odds ratio p-value
(95% CI) (95% CI)
Adherence over 4 months (per 10% increase) −0.46 (−0.66 to −0.26) <0.001 −0.73 (−1.34 to −0.12) <0.001
Time on second line ART First year referent referent
After first year 0.26 (−0.29 to 0.80) 0.358 1.05 (−0.12 to 2.23) 0.078
Sex Male 0.72 (−0.21 to 1.66) 0.131 0.93 (−0.53 to 2.39) 0.214
Female referent referent
Age (years) <26 1.7 (−2.16 to 5.57) 0.387 2.28 (−1.98 to 6.55) 0.294
≥26 referent referent
Log10 Viral load (copies/ml) at baseline 0.31 (−0.26 to 0.87) 0.286 0.53 (−0.36 to 1.43) 0.244
Square-root CD4 (cells/μL) at baseline −0.23 (−0.36 to −0.11) <0.001 −0.22 (−0.35 to −0.09) <0.001
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electronic dispensing, without incurring large additional
costs.
Our study has several limitations. First, the rate of VF
on second line in the McCord ART clinic was lower than
reported in a recent systematic review of second line treat-
ment outcomes in resource limited settings, possibly due
to a high physician/nurse to patient ratio and reliable anti-
retroviral drug supply [2]. Therefore the findings may not
be generalisable to public sector ART clinics in other set-
tings. Second, pharmacy staff shortages in clinics with large
patient numbers may be unable to apply the “interval gap”
method to calculate adherence. However, the “interval
crude” method, which is easy to calculate, could be insti-
tuted in pharmacies with staff shortages or those that only
keep manual pharmacy refill records. Third, we excluded
patients with zero adherence and suppressed VL on the
grounds that they must have been collecting ART at an-
other clinic. However, we had no way of determining this
and it is possible that other patients may also have col-
lected ART at other clinics, which would weaken associa-
tions between adherence and the virologic outcomes we
assessed. Fourth, we lacked power for some of the associa-
tions we assessed, notably the duration of second line ART
and risk for VF, and the determination of an adherence
threshold for virologic suppression.
Conclusion
In conclusion, short term pharmacy refill is an easily
implementable adherence measure that can be used in
ART clinics to identify patients at risk of VF on second
line ART. Future studies need to be conducted in larger
cohorts from clinics with a range of virologic outcomes
in order to determine a threshold of adherence for pre-
dicting virologic response and to evaluate whether VL
testing and GART could be limited to patients with bet-
ter adherence.
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